Research and development efficiency has been in decline for many years, but now with bodies, like the FDA, aiming to accelerate approval times and a critical need for new therapies to combat antibiotic resistant strains of bacteria will we see the tide turn?
Turning the tide
With demand for drug delivery technologies rising on a global scale1,2 and emerging markets offering increased opportunities to pharmaceutical companies in several areas is it any wonder research and development (R&D) has taken a back seat?